AstraZeneca PLC
Company History
AstraZeneca History: Founding, Growth & Key Milestones
Founded 1999 in Cambridge, United Kingdom
When was AstraZeneca founded?
AstraZeneca was founded in 1999 in Cambridge, United Kingdom by Sir David Barnes and Håkan Mogren, making it 27 years old.
- Founded
- 1999
- Founding place
- Cambridge, United Kingdom
- Founders
- Sir David Barnes and Håkan Mogren
- Headquarters today
- Cambridge, England
- Milestones documented
- 22 (1913–2026)
- Current CEO
- Pascal Soriot
- Acquisitions
- 8
| Year | Event |
|---|---|
| 1913 | Astra AB Founded in Södertälje, Sweden |
| 1993 | Zeneca Group Spun Off from ICI |
| 1999 | Astra and Zeneca Merge to Form AstraZeneca |
| 2000 | Nexium Launch Replaces Prilosec |
| 2006 | Acquisition of Cambridge Antibody Technology |
| 2007 | Acquisition of MedImmune for $15.6 Billion |
| 2012 | Pascal Soriot Appointed CEO |
| 2014 | Pfizer Hostile Takeover Rejected |
| 2014 | Acquisition of Almirall Respiratory Portfolio |
| 2015 | Tagrisso Approved for EGFR-Mutated Lung Cancer |
| 2017 | Imfinzi Approved Based on PACIFIC Trial |
| 2020 | COVID-19 Vaccine Development with Oxford University |
| 2021 | Acquisition of Alexion Pharmaceuticals for $39 Billion |
| 2023 | CinCor Pharma Acquired for up to $1.8 Billion |
| 2024 | Total Revenue Reaches $54.073 Billion |
| 2024 | Fusion Pharmaceuticals and Gracell Acquisitions |
| 2025 | Total Revenue Reaches $58.739 Billion |
| 2025 | EsoBiotec Acquired for Up to $1 Billion |
| 2025 | $50 Billion US Manufacturing and R&D Commitment |
| 2026 | Ordinary Shares Begin Trading on the NYSE |
| 2026 | Baxfendy Approved in the US for Hypertension |
| 2026 | $15 Billion China Investment Through 2030 |
- Where was AstraZeneca founded?
- AstraZeneca was founded in Cambridge, United Kingdom in 1999.
- Who founded AstraZeneca?
- AstraZeneca was founded by Sir David Barnes and Håkan Mogren.
- When did AstraZeneca start?
- AstraZeneca was founded in 1999.
- How old is AstraZeneca?
- AstraZeneca is 27 years old as of 2026.
Founding Story
The company was formed in 1999 by the merger of two national champions: Sweden's Astra and the UK's Zeneca, itself demerged from Imperial Chemical Industries in 1993. The defining moment of the modern company came in 2014, when Pfizer pursued AstraZeneca and made a final proposal of 55.00 pounds per share, valuing it at about 69 billion pounds or $117 billion. The board rejected that proposal on 19 May 2014, with CEO Pascal Soriot arguing that it undervalued the oncology pipeline and that integration would disrupt research. AstraZeneca stayed independent, and the medicines then in development, Tagrisso, Imfinzi and Enhertu, became the core of its growth.
Founders
Sir David Barnes
Sir David Barnes was chief executive of Zeneca Group plc, the company created when Imperial Chemical Industries demerged its pharmaceuticals, agrochemicals and specialty chemicals businesses in 1993, and he led the Zeneca side of the negotiations that produced AstraZeneca. The boards of Astra and Zeneca agreed terms for an all-share merger of equals on 9 December 1998 and the deal completed on 6 April 1999, with Zeneca shareholders holding 53.5% of the new company and Astra shareholders 46.5%. Barnes became deputy chairman of AstraZeneca after the merger. In 2014 he publicly opposed Pfizer's approach for the company, arguing the proposal was built on financial engineering rather than science. He died in 2020. (Exact birth year remains publicly undisclosed).
Håkan Mogren
Håkan Mogren was chief executive of Astra AB and negotiated the Swedish side of the 1999 merger with Zeneca Group alongside Sir David Barnes. Astra had grown into Scandinavia's largest pharmaceutical company on the strength of Losec (omeprazole), the proton pump inhibitor its researchers discovered, which became the best-selling medicine in the world in the 1990s. Mogren became non-executive deputy chairman of AstraZeneca after the merger and served on the board until 2009. (Exact birth year remains publicly undisclosed).
Key Milestones
Astra AB Founded in Södertälje, Sweden
400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies. The cooperative structure emphasized local production and scientific research, with initial products including antiseptics and anesthetics.
Source: en.wikipedia.orgZeneca Group Spun Off from ICI
Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales. The demerger creates the first major UK-focused pharmaceutical company since Glaxo's formation.
Source: en.wikipedia.orgAstra and Zeneca Merge to Form AstraZeneca
The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC. Zeneca shareholders receive 53.5% of the new company and Astra shareholders 46.5%, producing a group valued at about $67 billion with combined annual sales of more than $15 billion and headquarters in London. The US Federal Trade Commission requires the divestiture of Zeneca's levobupivacaine rights to preserve competition in long-acting local anaesthetics.
Source: en.wikipedia.orgNexium Launch Replaces Prilosec
AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001. Nexium became the company's flagship gastrointestinal product with peak annual sales above $5 billion before its US patent expired in May 2014.
Source: en.wikipedia.orgAcquisition of Cambridge Antibody Technology
AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion. The phage display antibody platform it acquires later supports Imfinzi, Fasenra and Tezspire, and signals a move toward large-molecule therapeutics.
Source: en.wikipedia.orgAcquisition of MedImmune for $15.6 Billion
AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.
Source: en.wikipedia.orgPascal Soriot Appointed CEO
Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment. Soriot immediately halts share buybacks and commits to increasing R&D spending.
Source: en.wikipedia.orgPfizer Hostile Takeover Rejected
AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential. The decision preserves independence but triggers short-term shareholder criticism.
Source: en.wikipedia.orgAcquisition of Almirall Respiratory Portfolio
AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.
Source: en.wikipedia.orgTagrisso Approved for EGFR-Mutated Lung Cancer
The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market. Tagrisso recorded $423 million of sales in 2016, its first full year, and grew to $7.25 billion by 2025.
Source: en.wikipedia.orgImfinzi Approved Based on PACIFIC Trial
The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits. The approval creates a new treatment category and establishes AstraZeneca in immuno-oncology.
Source: en.wikipedia.orgCOVID-19 Vaccine Development with Oxford University
AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak. The vaccine generates $3.9 billion in 2021 revenue before demand declines.
Source: en.wikipedia.orgAcquisition of Alexion Pharmaceuticals for $39 Billion
AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston. The acquisition adds $6 billion in immediate annual revenue.
Source: en.wikipedia.orgCinCor Pharma Acquired for up to $1.8 Billion
AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension. Baxdrostat was approved in the US as Baxfendy in May 2026.
Source: en.wikipedia.orgTotal Revenue Reaches $54.073 Billion
AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.
Source: en.wikipedia.orgFusion Pharmaceuticals and Gracell Acquisitions
AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.
Source: en.wikipedia.orgTotal Revenue Reaches $58.739 Billion
AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.
Source: en.wikipedia.orgEsoBiotec Acquired for Up to $1 Billion
AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.
Source: en.wikipedia.org$50 Billion US Manufacturing and R&D Commitment
AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion. In October 2025 it agreed with the US government to lower medicine prices for American patients in exchange for a three-year delay to Section 232 tariffs.
Source: astrazeneca-us.comOrdinary Shares Begin Trading on the NYSE
AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026. Trading is now harmonised across the NYSE, the London Stock Exchange and Nasdaq Stockholm.
Source: astrazeneca.comBaxfendy Approved in the US for Hypertension
The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled. The medicine came from the 2023 CinCor Pharma acquisition and the Phase III BaxHTN trial.
Source: astrazeneca.com$15 Billion China Investment Through 2030
AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue. The commitment follows the $2.5 billion Beijing research centre announced in March 2025.
Source: astrazeneca.comMajor Acquisitions
Alexion Pharmaceuticals
2021AstraZeneca acquired Alexion to enter the rare disease market with a proven complement-biology platform, gaining Soliris and Ultomiris as immediate blockbuster revenue drivers and establishing a dedicated rare disease unit headquartered in Boston. The acquisition provided scientific expertise in immunology that AstraZeneca lacked internally, along with specialized commercial infrastructure for ultra-rare disease diagnosis and patient identification.
MedImmune
2007AstraZeneca acquired MedImmune to gain biologics manufacturing capabilities, antibody technology platforms, and the Synagis respiratory syncytial virus franchise. The deal represented AstraZeneca's recognition that the future of pharmaceutical innovation lay in large-molecule biologics rather than small-molecule chemistry alone.
Cambridge Antibody Technology
2006AstraZeneca agreed in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion, after a collaboration begun in 2004 and having already held 19.2% of the shares.
Almirall Respiratory Portfolio
2014AstraZeneca acquired the respiratory portfolio of Spanish pharmaceutical company Almirall, including Eklira and rights to a pipeline of COPD and asthma candidates, to strengthen its position in the respiratory market ahead of Symbicort's patent expiration.
Fusion Pharmaceuticals
2024AstraZeneca acquired Fusion Pharmaceuticals for $2 billion in cash to access radiopharmaceutical and antibody-drug conjugate technologies, particularly the targeted alpha therapies platform that delivers potent radioisotopes directly to cancer cells.
Gracell Biotechnologies
2024AstraZeneca acquired Gracell Biotechnologies for $1.2 billion to access autologous cell therapy manufacturing capabilities and the FasTCAR platform, which reduces CAR-T production time from weeks to days.
CinCor Pharma
2023AstraZeneca agreed on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash at closing plus a non-tradable contingent value right of $10 per share on a specified baxdrostat regulatory submission, to add an aldosterone synthase inhibitor for hard-to-control hypertension.
EsoBiotec
2025AstraZeneca acquired Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology that delivers CAR-T genetic modifications directly within the patient's body, eliminating the need for ex vivo manufacturing.
Keep researching AstraZeneca
AstraZeneca Company History FAQ
What were the major milestones in the 1999 merger creating AstraZeneca?
The boards of Astra AB and Zeneca Group agreed terms for an all-share merger of equals on 9 December 1998, and the merger completed on 6 April 1999. The new company was valued at about $67 billion, had combined annual sales of more than $15 billion, and listed on the London Stock Exchange, Nasdaq in New York and the Stockholm exchange.
How did AstraZeneca commercialize Nexium (esomeprazole) in 2001?
In 2001, AstraZeneca launched Nexium (the single-isomer successor to Losec/Prilosec), executing one of the most successful commercial pharmaceutical launches in history and generating over $5 billion in annual peak sales.
What occurred during Pfizer's $117 billion hostile takeover attempt of AstraZeneca in 2014?
In May 2014, Pfizer launched a £69 billion ($117B) hostile takeover attempt to acquire AstraZeneca for tax-inversion purposes; CEO Pascal Soriot successfully rallied shareholders, UK Parliament, and scientists to reject the bid and preserve AstraZeneca's independence.
When was Tagrisso (osimertinib) approved and how did it transform lung cancer care?
The FDA approved Tagrisso in November 2015 for EGFR T790M lung cancer and later as first-line therapy (FLAURA trial), becoming a $5.8B+ annual blockbuster that significantly extended progression-free survival in non-small cell lung cancer.
How did AstraZeneca develop and distribute the Oxford-AstraZeneca COVID-19 vaccine?
In April 2020, AstraZeneca partnered with Oxford University to manufacture Vaxzevria at not-for-profit pricing, building a global supply chain across 15 countries that delivered over 3 billion doses, predominantly to low- and middle-income nations.
When did AstraZeneca acquire Alexion Pharmaceuticals for $39 billion?
In July 2021, AstraZeneca completed the $39 billion acquisition of Alexion Pharmaceuticals, immediately transforming AstraZeneca into a global leader in rare disease immunology and complement biology.
When was the landmark DESTINY-Breast04 clinical trial for Enhertu published?
In June 2022, AstraZeneca and Daiichi Sankyo presented the historic DESTINY-Breast04 trial results at ASCO, proving Enhertu doubled progression-free survival in HER2-low metastatic breast cancer, receiving a standing ovation from oncologists worldwide.
What are AstraZeneca's strategic milestones targeting $80 billion in revenue by 2030?
AstraZeneca's 2030 roadmap targets launching 20 new molecular medicines across oncology (ADCs, cell therapy), CVRM (oral weight loss, CKD), and rare disease, aiming to generate $80 billion in total annual revenue by 2030.
When was AstraZeneca founded?
The modern company was formed in 1999 through a massive $31.8 billion mega-merger of Swedish pharmaceutical company Astra AB and British chemical company Zeneca Group.
Related Companies
Compare AstraZeneca PLC History With Competitors
Related Strategic History
Compare founding milestones and corporate evolution
Explore AstraZeneca
Core profile pages, founders and related research hubs for this company.